{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:13:37Z","timestamp":1783548817992,"version":"3.55.0"},"reference-count":23,"publisher":"Japan Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej18-0506","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T22:03:52Z","timestamp":1574287432000},"page":"249-255","source":"Crossref","is-referenced-by-count":4,"title":["Association between circulating zinc-\u03b12-glycoprotein levels and the different phenotypes of polycystic ovary syndrome"],"prefix":"10.1507","volume":"67","author":[{"given":"Chenchen","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Endocrinology, 9th People\u2019s Hospital of Chongqing, Beibei City, Chongqong, 400700, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Children\u2019s Hospital of Chongqing Medical University, Yuzhong City, Chongqing 400014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiguo","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 9th People\u2019s Hospital of Chongqing, Beibei City, Chongqong, 400700, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 9th People\u2019s Hospital of Chongqing, Beibei City, Chongqong, 400700, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingrong","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 9th People\u2019s Hospital of Chongqing, Beibei City, Chongqong, 400700, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, et al. (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91: 456\u2013488.","DOI":"10.1016\/j.fertnstert.2008.06.035"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, et al. (2012) Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 33: 812\u2013841.","DOI":"10.1210\/er.2012-1003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Reaven GM (2005) The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 25: 391\u2013406.","DOI":"10.1146\/annurev.nutr.24.012003.132155"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33: 981\u20131030.","DOI":"10.1210\/er.2011-1034"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Carmina E, Lobo RA (2004) Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 82: 661\u2013665.","DOI":"10.1016\/j.fertnstert.2004.01.041"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 DeUgarte CM, Bartolucci A A, Azziz R (2005) Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83: 1454\u20131460.","DOI":"10.1016\/j.fertnstert.2004.11.070"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548\u20132556.","DOI":"10.1210\/jc.2004-0395"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115: 911\u2013920.","DOI":"10.1016\/j.jaci.2005.02.023"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, et al. (2005) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579: 41\u201347.","DOI":"10.1016\/j.febslet.2004.11.042"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Yeung DC, Lam KS, Wang Y, Tso AW, Xu A (2009) Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. J Clin Endocrinol Metab 94: 2531\u20132536.","DOI":"10.1210\/jc.2009-0058"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Eckardt K, Schober A, Platzbecker B, Mracek T, Bing C, et al. (2011) The adipokine zinc-alpha2-glycoprotein activates AMP kinase in human primary skeletal muscle cells. Arch Physiol Biochem 117: 88\u201393.","DOI":"10.3109\/13813455.2011.560950"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Yang M, Liu R, Li S, Luo Y, Zhang Y, et al. (2013) Zinc-alpha2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 36: 1074\u20131082.","DOI":"10.2337\/dc12-0940"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Tian M, Liang Z, Liu R, Li K, Tan X, et al. (2016) Effects of sitagliptin on circulating zinc-alpha2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial. Eur J Endocrinol 174: 147\u2013155.","DOI":"10.1530\/EJE-15-0637"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Lai Y, Chen J, Li L, Yin J, He J, et al. (2016) Circulating Zinc-alpha2-glycoprotein levels and insulin resistance in polycystic ovary syndrome. Sci Rep 6: 25934.","DOI":"10.1038\/srep25934"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensusn Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81: 19\u201325.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640\u20131645.","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Luo Y, Li L, Xu X, Wu T, Yang M, et al. (2017) Decreased circulating BMP-9 levels in patients with Type 2 diabetes is a signature of insulin resistance. Clin Sci (Lond) 131: 239\u2013246.","DOI":"10.1042\/CS20160543"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Jia Y, Yuan L, Hu W, Luo Y, Suo L, et al. (2014) Zinc-finger BED domain-containing 3 (Zbed3) is a novel secreted protein associated with insulin resistance in humans. J Intern Med 275: 522\u2013533.","DOI":"10.1111\/joim.12170"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214\u2013E223.","DOI":"10.1152\/ajpendo.1979.237.3.E214"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R (2000) Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43: 1507\u20131511.","DOI":"10.1007\/s001250051561"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kabil SL, Mahmoud NM (2018) Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation. Eur J Pharmacol 828: 135\u2013145.","DOI":"10.1016\/j.ejphar.2018.03.043"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Gao SX, Guo J, Fan GQ, Qiao Y, Zhao RQ, et al. (2018) ZAG alleviates HFD-induced insulin resistance accompanied with decreased lipid depot in skeletal muscle in mice. J Lipid Res 59: 2277\u20132286.","DOI":"10.1194\/jlr.M082180"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Xiao XH, Wang YD, Qi XY, Wang YY, Li JY, et al. (2018) Zinc alpha2 glycoprotein protects against obesity-induced hepatic steatosis. Int J Obes (Lond) 42: 1418\u20131430.","DOI":"10.1038\/s41366-018-0151-9"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/3\/67_EJ18-0506\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T03:43:16Z","timestamp":1585366996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/3\/67_EJ18-0506\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej18-0506","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}